ALIGOS THERAPEUTICS INC's ticker is ALGS and the CUSIP is 01626L105. A total of 69 filers reported holding ALIGOS THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $555,182 | -23.1% | 743,215 | 0.0% | 0.22% | -7.1% |
| Q2 2023 | $721,662 | +11.1% | 743,215 | 0.0% | 0.24% | -10.9% |
| Q1 2023 | $649,570 | -8.3% | 743,215 | 0.0% | 0.27% | -13.3% |
| Q4 2022 | $708,284 | -13.4% | 743,215 | 0.0% | 0.31% | +3.0% |
| Q3 2022 | $818,000 | -9.0% | 743,215 | 0.0% | 0.30% | -34.0% |
| Q2 2022 | $899,000 | -52.3% | 743,215 | -15.2% | 0.45% | -49.2% |
| Q1 2022 | $1,885,000 | -81.9% | 876,548 | 0.0% | 0.89% | -79.5% |
| Q4 2021 | $10,405,000 | -23.5% | 876,548 | 0.0% | 4.35% | -9.4% |
| Q3 2021 | $13,595,000 | -23.9% | 876,548 | 0.0% | 4.80% | -31.8% |
| Q2 2021 | $17,873,000 | -10.3% | 876,548 | 0.0% | 7.04% | +10.1% |
| Q1 2021 | $19,933,000 | -17.8% | 876,548 | 0.0% | 6.40% | -20.0% |
| Q4 2020 | $24,237,000 | – | 876,548 | – | 7.99% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 2,320,381 | $1,733,325 | 0.92% |
| TANG CAPITAL MANAGEMENT LLC | 3,329,048 | $2,486,799 | 0.35% |
| Vivo Capital, LLC | 3,547,030 | $2,649,631 | 0.29% |
| Pivotal bioVenture Partners Investment Advisor LLC | 743,215 | $555,182 | 0.22% |
| Newtyn Management, LLC | 920,000 | $687,240 | 0.17% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 631,887 | $472,020 | 0.14% |
| EcoR1 Capital, LLC | 3,948,360 | $2,949,425 | 0.10% |
| HHLR ADVISORS, LTD. | 2,309,764 | $1,725,394 | 0.04% |
| Baker Brothers Advisors | 2,076,400 | $1,551,071 | 0.01% |
| HARBOURVEST PARTNERS LLC | 18,783 | $14,031 | 0.01% |